Tackling the world’s deadliest diseases one Ab at a time: An interview with AbCellera’s CEO, Dr. Carl Hansen
Dr. Carl Hansen, CEO of AbCellera, a Vancouver-based biotech on the hunt for novel antibodies. Can one company simultaneously work on solving the problems of Ebola, influenza, neurodegeneration, cancer, tuberculosis, and enterotoxicogenic E. coli? If you are AbCellera, a Vancouver-based biotech on the hunt for novel antibodies that can be used to fight these diseases, the answer is yes. The company has built the world’s leading platform for the discovery of monoclonal antibodies and the profiling of natural immune responses. This proprietary platform, which uses a combination of microfluidics, genomics, microscopy, and machine learning, allows for screening millions of [...]